Provention Bio Investor Presentation March 2022

Provention Bio presents its strategy to intercept autoimmune disease through early immunotherapy intervention, focusing on teplizumab development and regulatory milestones. The presentation outlines the company's vision to prevent irreversible tissue damage in the 23+ million US patients living with autoimmune disease, challenging the traditional late-stage treatment paradigm.